These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 8450038)
21. Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lang AB; Schaad UB; Rüdeberg A; Wedgwood J; Que JU; Fürer E; Cryz SJ J Pediatr; 1995 Nov; 127(5):711-7. PubMed ID: 7472821 [TBL] [Abstract][Full Text] [Related]
22. Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis. Pier GB; Saunders JM; Ames P; Edwards MS; Auerbach H; Goldfarb J; Speert DP; Hurwitch S N Engl J Med; 1987 Sep; 317(13):793-8. PubMed ID: 2957591 [TBL] [Abstract][Full Text] [Related]
23. Pseudomonas aeruginosa infection in cystic fibrosis. Distribution of B and T lymphocytes in relation to the humoral immune response. Hoiby N; Mathiesen L Acta Pathol Microbiol Scand B Microbiol Immunol; 1974 Aug; 82(4):559-66. PubMed ID: 4213329 [No Abstract] [Full Text] [Related]
24. Relative increase in IgG antibodies to Pseudomonas aeruginosa 60-kDa GroEL in prediabetic patients with cystic fibrosis. Jensen P; Johansen HK; Lanng S; Høiby N Pediatr Res; 2001 Mar; 49(3):423-8. PubMed ID: 11228271 [TBL] [Abstract][Full Text] [Related]
25. Lipopolysaccharide (LPS), LPS-immune complexes and cytokines as inducers of pulmonary inflammation in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection. Kronborg G APMIS Suppl; 1995; 50():1-30. PubMed ID: 7756034 [TBL] [Abstract][Full Text] [Related]
26. Correlation of serum opsonic activity in cystic fibrosis with colonization and disease state: measurement of opsonins to Pseudomonas aeruginosa by neutrophil superoxide anion generation. Bender JG; Florman AL; Van Epps DE Pediatr Res; 1987 Oct; 22(4):383-8. PubMed ID: 2825106 [TBL] [Abstract][Full Text] [Related]
27. Serotype-specific serum IgG antibodies to lipopolysaccharides of Pseudomonas aeruginosa in cystic fibrosis: correlation to disease, subclass distribution, and experimental protective capacity. Schaad UB; Lang AB; Wedgwood J; Buehlamnn U; Fuerer E Pediatr Res; 1990 May; 27(5):508-13. PubMed ID: 2111907 [TBL] [Abstract][Full Text] [Related]
28. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. Ratjen F; Walter H; Haug M; Meisner C; Grasemann H; Döring G Pediatr Pulmonol; 2007 Mar; 42(3):249-55. PubMed ID: 17243185 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of polymorphonuclear leukocyte chemotaxis by the mucoid exopolysaccharide of Pseudomonas aeruginosa. Stiver HG; Zachidniak K; Speert DP Clin Invest Med; 1988 Aug; 11(4):247-52. PubMed ID: 2971496 [TBL] [Abstract][Full Text] [Related]
31. Pseudomonas aeruginosa infection in cystic fibrosis. Bactericidal effect of serum from normal individuals and patients with cystic fibrosis on P. aeruginosa strains from patients with cystic fibrosis or other diseases. Holby N; Olling S Acta Pathol Microbiol Scand C; 1977 Apr; 85(2):107-14. PubMed ID: 404841 [TBL] [Abstract][Full Text] [Related]
32. [Passive immunotherapy for treatment of endobronchitis in cystic fibrosis]. Moss RB Infusionsther Transfusionsmed; 1993 Apr; 20 Suppl 1():42-6; discussion 47. PubMed ID: 8499750 [TBL] [Abstract][Full Text] [Related]